**Supplemental Table 3A. Validation of gene array by qPCR of specific**

**genes altered by PA and ER interventions when tumors were equal in size.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Tum vol. @ 0.05-0.2 cm3 | Taqman PCR | | | Tumor gene array | | |
| PA+AL | SED+ER | PA+ER | PA+AL | SED+ER | PA+ER |
| *Ccl20* | -2.879 | -6.918 | -2.687 | -2.042 | -5.065 | -3.635 |
| *Cxcl5* | 2.606 | 1.898 | 1.506 | 4.439 | 3.637 | 1.377 |
| *Ifng* | 1.520 | -5.687 | -2.716 | 1.977 | -4.770 | -1.813 |
| *Foxp3* | 1.106 | -2.463 | -1.227 | 1.441 | -2.071 | -1.365 |
| *Pdcd1* | -1.878 | -3.457 | -1.555 | -1.356 | -3.033 | -1.321 |
| *Ido1* | -2.337 | -6.142 | -6.335 | -1.632 | -5.341 | -5.260 |

**Supplemental Table 3B. Validation of gene array by qPCR of specific genes altered**

**by PA and ER interventions when tumors were at day 35 post-tumor implantation.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Day 35 | Taqman PCR | | | Tumor gene array | | |
| PA+AL | SED+ER | PA+ER | PA+AL | SED+ER | PA+ER |
| *Ccl20* | -1.369 | 1.046 | -1.117 | -2.626 | -1.996 | -3.553 |
| *Ifng* | 1.115 | -2.054 | -1.576 | -1.311 | -2.480 | -1.841 |
| *Foxp3* | -1.058 | -3.121 | -1.555 | -1.334 | -2.542 | -1.829 |
| *Ido1* | -1.231 | -2.549 | -2.575 | -1.762 | -2.481 | -3.295 |